Incentivio is a developer of an intelligent guest engagement platform designed to enhance the restaurant experience in the digital age. The platform aims to help restaurants acquire new customers, increase visit frequency and spending, and foster customer loyalty. By leveraging technology, Incentivio enables restaurants to build meaningful relationships with their guests, ultimately driving digital revenue. Additionally, the platform helps reduce operational costs and generates incremental revenue, positioning restaurants to thrive in a competitive market.
Verve Motion specializes in the development of lightweight wearable exo-suits aimed at enhancing the safety and comfort of workers engaged in physically demanding tasks. By integrating robotics, apparel design, and movement science, the company creates innovative textile-based solutions that adapt to the movements of the wearer. These exo-suits provide support by delivering force at critical moments while remaining nonrestrictive, thereby promoting a safer work environment. Additionally, Verve Motion's designs contribute to a more restful experience for workers during their off-hours.
Operator of a biotechnology platform intended to increase binding affinity and improve consistency to help create personalized, precision cancer vaccines for patients of all backgrounds. The company's platform focuses on developing a single-molecule, massively parallel, de novo next-generation protein sequencing platform, enabling scientists and researchers to develop novel therapeutics and diagnostics and ultimately understand human biology and disease.
Ribon Therapeutics, Inc. is a biotechnology company based in Lexington, Massachusetts, founded in 2015. The company is focused on developing innovative cancer therapies that target monoPARP proteins, which are essential regulators of cancer cell survival. Ribon's scientific founders have made significant contributions to the understanding of PARPs, or poly(ADP-ribose) polymerases, and their roles in cancer. Leveraging this expertise, Ribon is establishing a proprietary drug discovery platform aimed at exploring the molecular actions and biological functions of monoPARPs. This platform supports the creation of a pipeline of therapeutics that selectively target these proteins to potentially treat cancer and other diseases. Ribon Therapeutics is supported by notable life science investors, enhancing its capability to advance its research and development efforts.
Pliant.io, Inc. is a technology company that specializes in infrastructure automation, providing a platform designed for IT operations to efficiently plan, build, and deploy API-level automations. Founded in 2017 and based in Boston, Massachusetts, Pliant offers an orchestration, automation, and response (OAR) platform that simplifies the development of IT automation solutions. Its platform features visual representations and low-code building blocks, enabling developers to automate complex processes across various domains. Use cases for Pliant's technology include virtual machine provisioning, server auditing and remediation, IT service management orchestration, hybrid network configuration, and application delivery and security. By streamlining automation, Pliant helps organizations respond to the evolving demands of their business processes while reducing human error and enhancing overall efficiency.
Connected2Fiber, Inc. provides a location-based insights platform tailored for network buyers and sellers in the United States. Founded in 2015 and based in Hopkinton, Massachusetts, the company offers a suite of solutions designed to enhance transparency and efficiency in the network industry. Its key offerings include the Connected World module, which visualizes fiber networks alongside market context, and the Building Manager module, which facilitates the management of various connected assets. The platform also features Building Intelligence for visualizing OnNet buildings and a Building List Manager for efficient contact and program management. Additionally, Connected2Fiber provides a Configure, Price, Quote (CPQ) tool that automates price quoting with detailed, location-based insights. The company's services cater to a range of sectors, including local exchange carriers, cable companies, competitive local exchange carriers, and municipal networks, enabling them to improve their marketing investments and operational outcomes.
EGenesis Inc. is a biotechnology company based in Cambridge, Massachusetts, with an additional office in New York. Founded in 2015, the company specializes in gene editing and genome engineering, focusing on the development of human-compatible organs, tissues, and cells for transplantation. EGenesis employs advanced gene editing techniques to create transplantable cells and solid organs, specifically targeting therapeutic applications in kidney and islet cell transplantation. By leveraging its innovative platform, the company aims to transform the field of organ transplantation, providing safe and effective solutions for patients with life-threatening diseases globally.
Artizan Biosciences develops small molecule drugs targeting human diseases, utilizing its IgA-SEQ technology platform to identify disease-driving bacteria within the intestinal microbiota. Founded in 2016 and headquartered in New Haven, Connecticut, the company focuses on creating new and potentially curative treatments. With a commitment to advancing pharmaceutical drug development, Artizan Biosciences aims to address unmet medical needs through innovative approaches in biotechnology.
Cyteir Therapeutics, Inc. focuses on developing innovative therapeutics that harness the biology of DNA repair to treat cancer and address autoimmune diseases through synthetic lethality. The company manufactures targeted therapeutics designed to induce the self-destruction of diseased cells by overwhelming them with DNA damage. Utilizing an integrated drug development platform, Cyteir aims to balance DNA damage and repair mechanisms to achieve therapeutic effects. Its diverse pipeline includes small molecule therapeutics intended for various applications, particularly in hematological malignancies, solid tumors, and chronic autoimmune disorders. Founded in 2012 and headquartered in Lexington, Massachusetts, Cyteir Therapeutics is committed to overcoming significant challenges in oncology, such as minimizing side effects, reducing therapy resistance, and promoting the self-destruction of cancerous cells.
Indico Data Solutions, Inc. is a Boston-based company that specializes in developing artificial intelligence solutions for automating the processing of unstructured content. Founded in 2013, Indico's platform allows enterprises to create customized machine learning models using smaller datasets, effectively enhancing the efficiency of labor-intensive document-based workflows. By focusing on automating tedious back-office tasks, Indico enables organizations to extract valuable insights from unstructured content, such as text and images. The company's innovative approach, known as transfer learning, empowers users to train machine learning models with significantly less data than traditional methods require. This capability helps businesses overcome common barriers to AI adoption, ultimately transforming their document processing into more profitable operations.
Q32 Bio is a biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases. Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief.
Q32 Bio consists of a team of scientists and industry veterans with strong expertise in immunology. The team has a strong track record of discovering and developing new and innovative therapies.
Q32 Bio is a biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases. Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief.
Q32 Bio consists of a team of scientists and industry veterans with strong expertise in immunology. The team has a strong track record of discovering and developing new and innovative therapies.
Nido Biosciences, Inc., founded in 2018 and based in Boston, Massachusetts, operates in the healthcare services sector. The company specializes in biotechnology and personal health, aiming to innovate within these fields. Currently in stealth mode, Nido Biosciences is focused on developing solutions that address unmet needs in healthcare and personal health management.
HelloTeam is a cloud-based engagement and talent management platform aimed at enhancing employee engagement and retention. The platform provides tools for driving employee goals, performance, and recognition, while also facilitating the development of data-driven people strategies. By leveraging real-time insights and analytics, HelloTeam helps organizations create a work environment where employees feel seen, heard, and valued. This focus on employee experience contributes to a more engaged and connected workforce, ultimately fostering a positive organizational culture.
Aerovate Therapeutics is a clinical-stage biotechnology company based in Boston, Massachusetts, dedicated to developing treatments for patients with rare cardiopulmonary diseases. The company's primary focus is on advancing AV-101, a proprietary inhaled dry powder formulation of the drug imatinib, designed to treat pulmonary arterial hypertension (PAH). This innovative delivery method targets diseased lung tissues directly, minimizing systemic side effects often associated with traditional therapies. Founded in 2018 and initially incubated by RA Capital Management, Aerovate aims to provide meaningful improvements to the lives of those affected by these serious conditions.
Vor Biopharma, Inc. develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It offers VOR33, an eHSC product candidate that is in preclinical development to treat acute myeloid leukemia (AML). The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML cancer cells. Vor Biopharma, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.
Vor Biopharma, Inc. develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It offers VOR33, an eHSC product candidate that is in preclinical development to treat acute myeloid leukemia (AML). The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML cancer cells. Vor Biopharma, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.
Cyteir Therapeutics, Inc. focuses on developing innovative therapeutics that harness the biology of DNA repair to treat cancer and address autoimmune diseases through synthetic lethality. The company manufactures targeted therapeutics designed to induce the self-destruction of diseased cells by overwhelming them with DNA damage. Utilizing an integrated drug development platform, Cyteir aims to balance DNA damage and repair mechanisms to achieve therapeutic effects. Its diverse pipeline includes small molecule therapeutics intended for various applications, particularly in hematological malignancies, solid tumors, and chronic autoimmune disorders. Founded in 2012 and headquartered in Lexington, Massachusetts, Cyteir Therapeutics is committed to overcoming significant challenges in oncology, such as minimizing side effects, reducing therapy resistance, and promoting the self-destruction of cancerous cells.
Connected2Fiber, Inc. provides a location-based insights platform tailored for network buyers and sellers in the United States. Founded in 2015 and based in Hopkinton, Massachusetts, the company offers a suite of solutions designed to enhance transparency and efficiency in the network industry. Its key offerings include the Connected World module, which visualizes fiber networks alongside market context, and the Building Manager module, which facilitates the management of various connected assets. The platform also features Building Intelligence for visualizing OnNet buildings and a Building List Manager for efficient contact and program management. Additionally, Connected2Fiber provides a Configure, Price, Quote (CPQ) tool that automates price quoting with detailed, location-based insights. The company's services cater to a range of sectors, including local exchange carriers, cable companies, competitive local exchange carriers, and municipal networks, enabling them to improve their marketing investments and operational outcomes.
Artizan Biosciences develops small molecule drugs targeting human diseases, utilizing its IgA-SEQ technology platform to identify disease-driving bacteria within the intestinal microbiota. Founded in 2016 and headquartered in New Haven, Connecticut, the company focuses on creating new and potentially curative treatments. With a commitment to advancing pharmaceutical drug development, Artizan Biosciences aims to address unmet medical needs through innovative approaches in biotechnology.
Twentyeight-Seven, Inc. is a biotechnology company based in Watertown, Massachusetts, specializing in the development of small molecules that modulate microRNAs (miRNAs) by targeting the proteins that interact with these molecules. Their innovative approach focuses on using short non-coding RNAs to inhibit gene expression, suppress mRNA translation, and promote mRNA decay. By targeting miRNAs that play a critical role in cancer initiation, progression, and metastasis, Twentyeight-Seven aims to create effective therapeutic solutions for cancer treatment.
Arrakis Therapeutics is a biopharmaceutical company focused on developing innovative drugs that target ribonucleic acid (RNA) to treat a variety of diseases, including cancer and rare genetic disorders. The company employs a unique drug discovery platform that integrates advanced RNA bioinformatics and structural tools, allowing it to identify new RNA targets and create RNA-targeted small molecules (rSMs). Its proprietary pipeline consists of these rSMs aimed at genetically validated targets across multiple disease areas. Additionally, Arrakis offers SHAPEware, a software tool that assists in predicting RNA secondary structures and potential ligand-binding sites. Founded in 2015 and based in Waltham, Massachusetts, Arrakis Therapeutics aims to enhance therapeutic options for patients through its cutting-edge research and development efforts.
Hyalex Orthopaedics, Inc. is a medical device company based in Lexington, Massachusetts, focused on developing innovative products that utilize HYALEX technology, a synthetic polymer engineered to mimic cartilage. Founded in 2016, the company specializes in creating a biomimetic material that can effectively simulate healthy cartilage to treat diseased or damaged joints. The unique properties of HYALEX allow it to maintain low friction and wear, even under the significant loads typically experienced in human joints. This capability enables surgeons to replace arthritic cartilage while preserving healthy bone. Although Hyalex Orthopaedics is advancing its product development, its offerings have not yet received approval for use in humans from any regulatory agency.
Vor Biopharma, Inc. develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It offers VOR33, an eHSC product candidate that is in preclinical development to treat acute myeloid leukemia (AML). The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML cancer cells. Vor Biopharma, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.
Ribon Therapeutics, Inc. is a biotechnology company based in Lexington, Massachusetts, founded in 2015. The company is focused on developing innovative cancer therapies that target monoPARP proteins, which are essential regulators of cancer cell survival. Ribon's scientific founders have made significant contributions to the understanding of PARPs, or poly(ADP-ribose) polymerases, and their roles in cancer. Leveraging this expertise, Ribon is establishing a proprietary drug discovery platform aimed at exploring the molecular actions and biological functions of monoPARPs. This platform supports the creation of a pipeline of therapeutics that selectively target these proteins to potentially treat cancer and other diseases. Ribon Therapeutics is supported by notable life science investors, enhancing its capability to advance its research and development efforts.
MC10, Inc. specializes in developing and selling wearable medical sensors that capture clinical-grade biometric and physiological data for use in clinical trials. Founded in 2008 and based in Lexington, Massachusetts, the company offers several innovative products, including BioStamp nPoint, which processes raw data into clinical metrics such as vital signs and sleep patterns; Kintinuum, a rehabilitation device for orthopedic surgery; WiSP, which provides cardiac monitoring and ECG recording; and BioStampMD, a flexible sensor designed to conform to the human body for comprehensive data collection. The BioStamp system enhances data acquisition by allowing for discreet and comfortable wear, thus facilitating targeted measurements of muscle activation and movement. MC10's dedication to creating flexible, conformal electronics aims to improve the quality of life by seamlessly integrating technology with human activity.
Spero Therapeutics, a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializes in developing novel therapies for multi-drug resistant (MDR) bacterial infections and rare diseases. Its key product candidates include tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic intended for adults with MDR Gram-negative infections, and SPR206, an intravenous agent targeting MDR Gram-negative infections in hospital settings. Additionally, the company is advancing SPR720, an oral antibiotic designed for treating pulmonary non-tuberculous mycobacterial disease. Spero Therapeutics has established various collaborations and license agreements to support the development and commercialization of its products, including partnerships with Meiji Seika Pharma, Everest Medicines, and the Bill & Melinda Gates Medical Research Institute. Founded in 2013, Spero aims to address the critical need for effective treatments against serious bacterial infections using innovative approaches and mechanisms.
Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing precision genetic medicines using its innovative base editing technology. This technology allows for targeted alterations of single bases in the genome without creating double-stranded breaks in DNA, representing a potential advancement in genetic therapies. The company's pipeline includes programs aimed at treating serious diseases such as sickle cell disease, beta-thalassemia, pediatric T-cell acute lymphoblastic leukemia, and pediatric acute myeloid leukemia, as well as conditions like alpha-1 antitrypsin deficiency and certain central nervous system disorders. Beam Therapeutics is committed to providing life-long cures through its various approaches, which include gene correction, gene modification, gene activation, gene silencing, and multiplex editing. Founded in 2017, Beam continues to build collaborations to enhance its research and development efforts.
Cyteir Therapeutics, Inc. focuses on developing innovative therapeutics that harness the biology of DNA repair to treat cancer and address autoimmune diseases through synthetic lethality. The company manufactures targeted therapeutics designed to induce the self-destruction of diseased cells by overwhelming them with DNA damage. Utilizing an integrated drug development platform, Cyteir aims to balance DNA damage and repair mechanisms to achieve therapeutic effects. Its diverse pipeline includes small molecule therapeutics intended for various applications, particularly in hematological malignancies, solid tumors, and chronic autoimmune disorders. Founded in 2012 and headquartered in Lexington, Massachusetts, Cyteir Therapeutics is committed to overcoming significant challenges in oncology, such as minimizing side effects, reducing therapy resistance, and promoting the self-destruction of cancerous cells.
Indico Data Solutions, Inc. is a Boston-based company that specializes in developing artificial intelligence solutions for automating the processing of unstructured content. Founded in 2013, Indico's platform allows enterprises to create customized machine learning models using smaller datasets, effectively enhancing the efficiency of labor-intensive document-based workflows. By focusing on automating tedious back-office tasks, Indico enables organizations to extract valuable insights from unstructured content, such as text and images. The company's innovative approach, known as transfer learning, empowers users to train machine learning models with significantly less data than traditional methods require. This capability helps businesses overcome common barriers to AI adoption, ultimately transforming their document processing into more profitable operations.
Connected2Fiber, Inc. provides a location-based insights platform tailored for network buyers and sellers in the United States. Founded in 2015 and based in Hopkinton, Massachusetts, the company offers a suite of solutions designed to enhance transparency and efficiency in the network industry. Its key offerings include the Connected World module, which visualizes fiber networks alongside market context, and the Building Manager module, which facilitates the management of various connected assets. The platform also features Building Intelligence for visualizing OnNet buildings and a Building List Manager for efficient contact and program management. Additionally, Connected2Fiber provides a Configure, Price, Quote (CPQ) tool that automates price quoting with detailed, location-based insights. The company's services cater to a range of sectors, including local exchange carriers, cable companies, competitive local exchange carriers, and municipal networks, enabling them to improve their marketing investments and operational outcomes.
Quantum Circuits, Inc., founded in 2015 and based in New Haven, Connecticut, specializes in the development, manufacturing, and sale of quantum computers utilizing superconducting devices. The company's primary objective is to create practical and useful quantum computers, while also commercializing components, devices, and software that support fundamental research and the scaling of quantum computing. Quantum Circuits focuses on the quantum circuit model, which facilitates universal and fault-tolerant operations through error correction. The technology employs superconducting Josephson junctions that function as solid-state quantum bits, or qubits. Founded by leading experts from Yale University's Department of Applied Physics, Quantum Circuits has made significant advancements in quantum devices and information processing, contributing to notable scientific achievements, including the development of a quantum bus for entangling qubits and the execution of quantum algorithms using solid-state devices.
Selecta Biosciences is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs aimed at treating and preventing human diseases. The company’s proprietary platform integrates advancements in immunobiology and nanotechnology to create targeted immunomodulatory nanoparticles. Its lead product, SEL-212, has completed Phase II clinical trials for chronic refractory gout. Additionally, Selecta is advancing gene therapy candidates, including SEL-302 and SEL-313, which are in preclinical development for rare metabolic disorders. The company has established collaborations and licensing agreements with various organizations, including Spark Therapeutics and the Massachusetts Institute of Technology. Founded in 2007 and headquartered in Watertown, Massachusetts, Selecta Biosciences continues to innovate in the biopharmaceutical field.
Homology Medicines, Inc. is a genetic medicines company based in Bedford, Massachusetts, focused on improving the lives of patients with rare genetic diseases. The company employs a proprietary platform that utilizes human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to deliver genetic therapies in vivo, either through gene therapy or nuclease-free gene editing. This innovative approach allows for targeted treatment of various disease-relevant tissues, including the liver and central nervous system, through a single injection. Homology's lead product candidate, HMI-102, is currently in a Phase 1/2 clinical trial for treating phenylketonuria (PKU) in adults, while HMI-103 targets pediatric PKU patients, and HMI-202 is being developed for metachromatic leukodystrophy. Founded in 2015, Homology Medicines aims to address significant unmet medical needs by targeting the underlying causes of genetic disorders.
Perceptive Automata, Inc. specializes in machine learning and computer vision technologies aimed at predicting human behavior to enhance the safety and efficacy of automated vehicles. Founded in 2014 and headquartered in Somerville, Massachusetts, the company addresses a critical challenge in automated driving: enabling vehicles to anticipate the actions of pedestrians, cyclists, and other drivers. This capability is vital for the smooth and safe operation of highly automated (L2/3) and fully autonomous (L4/5) vehicles, particularly in urban environments. By leveraging advanced AI that surpasses conventional physics-based models, Perceptive Automata facilitates a more natural driving experience and promotes the acceptance of autonomous vehicles in human-dominated road scenarios. The company collaborates with original equipment manufacturers, suppliers, and technology firms involved in the development of advanced driver-assistance systems and autonomous driving solutions, drawing on a team of experts from esteemed institutions such as Harvard, MIT, and Stanford.
Hyalex Orthopaedics, Inc. is a medical device company based in Lexington, Massachusetts, focused on developing innovative products that utilize HYALEX technology, a synthetic polymer engineered to mimic cartilage. Founded in 2016, the company specializes in creating a biomimetic material that can effectively simulate healthy cartilage to treat diseased or damaged joints. The unique properties of HYALEX allow it to maintain low friction and wear, even under the significant loads typically experienced in human joints. This capability enables surgeons to replace arthritic cartilage while preserving healthy bone. Although Hyalex Orthopaedics is advancing its product development, its offerings have not yet received approval for use in humans from any regulatory agency.
Spero Therapeutics, a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializes in developing novel therapies for multi-drug resistant (MDR) bacterial infections and rare diseases. Its key product candidates include tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic intended for adults with MDR Gram-negative infections, and SPR206, an intravenous agent targeting MDR Gram-negative infections in hospital settings. Additionally, the company is advancing SPR720, an oral antibiotic designed for treating pulmonary non-tuberculous mycobacterial disease. Spero Therapeutics has established various collaborations and license agreements to support the development and commercialization of its products, including partnerships with Meiji Seika Pharma, Everest Medicines, and the Bill & Melinda Gates Medical Research Institute. Founded in 2013, Spero aims to address the critical need for effective treatments against serious bacterial infections using innovative approaches and mechanisms.
Arrakis Therapeutics is a biopharmaceutical company focused on developing innovative drugs that target ribonucleic acid (RNA) to treat a variety of diseases, including cancer and rare genetic disorders. The company employs a unique drug discovery platform that integrates advanced RNA bioinformatics and structural tools, allowing it to identify new RNA targets and create RNA-targeted small molecules (rSMs). Its proprietary pipeline consists of these rSMs aimed at genetically validated targets across multiple disease areas. Additionally, Arrakis offers SHAPEware, a software tool that assists in predicting RNA secondary structures and potential ligand-binding sites. Founded in 2015 and based in Waltham, Massachusetts, Arrakis Therapeutics aims to enhance therapeutic options for patients through its cutting-edge research and development efforts.
Biohaven is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline products include BHV3000-301, BHV3000-302, BHV3000-303, and others.
Spero Therapeutics, a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializes in developing novel therapies for multi-drug resistant (MDR) bacterial infections and rare diseases. Its key product candidates include tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic intended for adults with MDR Gram-negative infections, and SPR206, an intravenous agent targeting MDR Gram-negative infections in hospital settings. Additionally, the company is advancing SPR720, an oral antibiotic designed for treating pulmonary non-tuberculous mycobacterial disease. Spero Therapeutics has established various collaborations and license agreements to support the development and commercialization of its products, including partnerships with Meiji Seika Pharma, Everest Medicines, and the Bill & Melinda Gates Medical Research Institute. Founded in 2013, Spero aims to address the critical need for effective treatments against serious bacterial infections using innovative approaches and mechanisms.
Ribon Therapeutics, Inc. is a biotechnology company based in Lexington, Massachusetts, founded in 2015. The company is focused on developing innovative cancer therapies that target monoPARP proteins, which are essential regulators of cancer cell survival. Ribon's scientific founders have made significant contributions to the understanding of PARPs, or poly(ADP-ribose) polymerases, and their roles in cancer. Leveraging this expertise, Ribon is establishing a proprietary drug discovery platform aimed at exploring the molecular actions and biological functions of monoPARPs. This platform supports the creation of a pipeline of therapeutics that selectively target these proteins to potentially treat cancer and other diseases. Ribon Therapeutics is supported by notable life science investors, enhancing its capability to advance its research and development efforts.
Ribon Therapeutics, Inc. is a biotechnology company based in Lexington, Massachusetts, founded in 2015. The company is focused on developing innovative cancer therapies that target monoPARP proteins, which are essential regulators of cancer cell survival. Ribon's scientific founders have made significant contributions to the understanding of PARPs, or poly(ADP-ribose) polymerases, and their roles in cancer. Leveraging this expertise, Ribon is establishing a proprietary drug discovery platform aimed at exploring the molecular actions and biological functions of monoPARPs. This platform supports the creation of a pipeline of therapeutics that selectively target these proteins to potentially treat cancer and other diseases. Ribon Therapeutics is supported by notable life science investors, enhancing its capability to advance its research and development efforts.
SevOne, Inc. specializes in infrastructure performance monitoring and analytics solutions for a global clientele, including communications service providers, government entities, financial institutions, and large enterprises. The company offers a comprehensive suite of products, including the SevOne Data Platform, which gathers multi-vendor network performance metrics and flow data, and the SevOne Data Insight, designed for customizable visualizations and workflows. Additionally, the SevOne Data Appliance analyzes network and infrastructure data, while the SevOne Data Bus streams real-time data. The SevOne Data Cloud provides both real-time and historical insights from network telemetry. The company also has solutions for monitoring software-defined networking (SDN) and SD-WAN for managed services providers. Founded in 2003 and headquartered in Boston, Massachusetts, SevOne has expanded its presence with additional offices in Newark, Delaware, and London, United Kingdom. As of late 2019, SevOne operates as a subsidiary of Turbonomic, Inc.
Selecta Biosciences is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs aimed at treating and preventing human diseases. The company’s proprietary platform integrates advancements in immunobiology and nanotechnology to create targeted immunomodulatory nanoparticles. Its lead product, SEL-212, has completed Phase II clinical trials for chronic refractory gout. Additionally, Selecta is advancing gene therapy candidates, including SEL-302 and SEL-313, which are in preclinical development for rare metabolic disorders. The company has established collaborations and licensing agreements with various organizations, including Spark Therapeutics and the Massachusetts Institute of Technology. Founded in 2007 and headquartered in Watertown, Massachusetts, Selecta Biosciences continues to innovate in the biopharmaceutical field.
Voxel8 Inc. is a company focused on advancing 3D printing technology by integrating electronic functionalities into traditional 3D printed structures. Established in 2013 and located in Somerville, Massachusetts, Voxel8 designs and manufactures desktop 3D printers capable of printing thermoplastics and UV resins. The company specializes in innovative materials that enable the embedding of conductors, wires, and batteries within standard 3D printing matrices, based on research from Harvard University. Additionally, Voxel8 offers Project Wire, a cloud-based software tool that assists users in designing 3D printable electronic devices that can be efficiently produced using their printers.
Jibo, Inc. specializes in the manufacture and sale of social robots designed for home use. The company's flagship product, Jibo, is engineered to interact with users using advanced Natural Language Understanding, speech recognition, and facial recognition technologies. This robot serves as an electronic companion, capable of learning user preferences, assisting with daily tasks, and providing reminders for important events. Jibo communicates through natural social and emotive cues, enhancing the user experience and facilitating meaningful interactions. Founded in 2012 and launched publicly in 2017, Jibo, Inc. operates from its headquarters in Boston, Massachusetts, serving a diverse market that includes the United States, Canada, various European countries, and parts of Asia and South America. The company's goal is to improve human-robot interaction, making everyday life simpler and more engaging for individuals of all ages.
Kolltan Pharmaceuticals, Inc. is a clinical-stage biotechnology company founded in 2007 and based in New Haven, Connecticut. The company focuses on the discovery and development of novel antibody-based drugs targeting receptor tyrosine kinases (RTKs) for the treatment of cancer and other diseases. Its lead product candidate, KTN3379, is an antibody targeting the ErbB3 RTK, currently undergoing Phase I clinical trials for advanced solid tumors. Additionally, Kolltan is developing KTN0158, a KIT RTK inhibitor aimed at treating neurofibromatosis type 1 and other inflammatory conditions, as well as an antibody-drug conjugate known as KIT-ADC for oncology applications. The company also engages in various research programs targeting RTKs, building on foundational discoveries made in collaboration with Dr. Joseph Schlessinger's laboratory at Yale University, which elucidate the molecular mechanisms linked to RTK activation and oncogenic mutations.
Infinio addresses the most expensive bottleneck in virtual environments: storage performance.
Data center administrators buy more storage hardware when what they really want is better storage performance. Infinio offers a software-only solution instead.
Infinio has strong financial backing from tier-one venture capitalists including Highland Capital Partners, Bessemer Venture Partners, Lightspeed Venture Partners and Osage University Partners.
Sideris Pharmaceuticals Inc. is a privately held biopharmaceutical company that is focused on development of therapeutics for the treatment of transfusion-related iron overload. The company’s operations include facilities in Boston, MA, and in Gainesville, FL.
Evolv Technology specializes in noninvasive body scanners designed for touchless security screening, focusing on enhancing safety in public spaces. The company offers a range of products, including Evolv Express for firearm and bomb detection, Evolv Edge for checkpoint security, and Evolv Pinpoint for facial recognition. These systems are utilized in various settings, such as schools, stadiums, hospitals, and entertainment venues, to ensure the safety of employees, visitors, and VIPs. Founded in 2013 and headquartered in Waltham, Massachusetts, Evolv Technology aims to improve security protocols by integrating advanced sensors and artificial intelligence, enabling reliable scanning without compromising the visitor experience. The company has screened over 50 million individuals, successfully preventing more than 5,000 weapons from entering secure areas. With a leadership team comprising veterans from security agencies, Evolv is committed to providing effective solutions for both government and private sectors.
BA Insight is a provider of integrated search technologies aimed at enhancing the use of Microsoft SharePoint across enterprises. Founded in 2004 and headquartered in New York City, the company offers products like Longitude Search and Longitude Connector, which enable organizations to extend Microsoft’s enterprise search capabilities across various systems, including CRM, ERP, and ECM. These solutions feature advanced document preview and assembly tools that enhance the efficiency of knowledge workers by facilitating quicker and more effective access to information. BA Insight serves a diverse clientele, including Fortune 500 companies and government agencies, helping millions of users optimize their information assets and improve productivity. The company is recognized for its AI-driven technology that incorporates machine learning and cognitive computing to streamline search processes within organizations.
MC10, Inc. specializes in developing and selling wearable medical sensors that capture clinical-grade biometric and physiological data for use in clinical trials. Founded in 2008 and based in Lexington, Massachusetts, the company offers several innovative products, including BioStamp nPoint, which processes raw data into clinical metrics such as vital signs and sleep patterns; Kintinuum, a rehabilitation device for orthopedic surgery; WiSP, which provides cardiac monitoring and ECG recording; and BioStampMD, a flexible sensor designed to conform to the human body for comprehensive data collection. The BioStamp system enhances data acquisition by allowing for discreet and comfortable wear, thus facilitating targeted measurements of muscle activation and movement. MC10's dedication to creating flexible, conformal electronics aims to improve the quality of life by seamlessly integrating technology with human activity.
MC10, Inc. specializes in developing and selling wearable medical sensors that capture clinical-grade biometric and physiological data for use in clinical trials. Founded in 2008 and based in Lexington, Massachusetts, the company offers several innovative products, including BioStamp nPoint, which processes raw data into clinical metrics such as vital signs and sleep patterns; Kintinuum, a rehabilitation device for orthopedic surgery; WiSP, which provides cardiac monitoring and ECG recording; and BioStampMD, a flexible sensor designed to conform to the human body for comprehensive data collection. The BioStamp system enhances data acquisition by allowing for discreet and comfortable wear, thus facilitating targeted measurements of muscle activation and movement. MC10's dedication to creating flexible, conformal electronics aims to improve the quality of life by seamlessly integrating technology with human activity.
BA Insight is a provider of integrated search technologies aimed at enhancing the use of Microsoft SharePoint across enterprises. Founded in 2004 and headquartered in New York City, the company offers products like Longitude Search and Longitude Connector, which enable organizations to extend Microsoft’s enterprise search capabilities across various systems, including CRM, ERP, and ECM. These solutions feature advanced document preview and assembly tools that enhance the efficiency of knowledge workers by facilitating quicker and more effective access to information. BA Insight serves a diverse clientele, including Fortune 500 companies and government agencies, helping millions of users optimize their information assets and improve productivity. The company is recognized for its AI-driven technology that incorporates machine learning and cognitive computing to streamline search processes within organizations.
MC10, Inc. specializes in developing and selling wearable medical sensors that capture clinical-grade biometric and physiological data for use in clinical trials. Founded in 2008 and based in Lexington, Massachusetts, the company offers several innovative products, including BioStamp nPoint, which processes raw data into clinical metrics such as vital signs and sleep patterns; Kintinuum, a rehabilitation device for orthopedic surgery; WiSP, which provides cardiac monitoring and ECG recording; and BioStampMD, a flexible sensor designed to conform to the human body for comprehensive data collection. The BioStamp system enhances data acquisition by allowing for discreet and comfortable wear, thus facilitating targeted measurements of muscle activation and movement. MC10's dedication to creating flexible, conformal electronics aims to improve the quality of life by seamlessly integrating technology with human activity.
Virdante Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the development and commercialization of drugs for autoimmune and inflammatory diseases. Founded in 2007 and previously known as Centaurus Pharmaceuticals, the company specializes in creating antibody and Fc-fusion therapies aimed at addressing various autoimmune conditions. Through its innovative research and development efforts, Virdante Pharmaceuticals seeks to improve treatment options for patients suffering from these disorders.
Kolltan Pharmaceuticals, Inc. is a clinical-stage biotechnology company founded in 2007 and based in New Haven, Connecticut. The company focuses on the discovery and development of novel antibody-based drugs targeting receptor tyrosine kinases (RTKs) for the treatment of cancer and other diseases. Its lead product candidate, KTN3379, is an antibody targeting the ErbB3 RTK, currently undergoing Phase I clinical trials for advanced solid tumors. Additionally, Kolltan is developing KTN0158, a KIT RTK inhibitor aimed at treating neurofibromatosis type 1 and other inflammatory conditions, as well as an antibody-drug conjugate known as KIT-ADC for oncology applications. The company also engages in various research programs targeting RTKs, building on foundational discoveries made in collaboration with Dr. Joseph Schlessinger's laboratory at Yale University, which elucidate the molecular mechanisms linked to RTK activation and oncogenic mutations.
SevOne, Inc. specializes in infrastructure performance monitoring and analytics solutions for a global clientele, including communications service providers, government entities, financial institutions, and large enterprises. The company offers a comprehensive suite of products, including the SevOne Data Platform, which gathers multi-vendor network performance metrics and flow data, and the SevOne Data Insight, designed for customizable visualizations and workflows. Additionally, the SevOne Data Appliance analyzes network and infrastructure data, while the SevOne Data Bus streams real-time data. The SevOne Data Cloud provides both real-time and historical insights from network telemetry. The company also has solutions for monitoring software-defined networking (SDN) and SD-WAN for managed services providers. Founded in 2003 and headquartered in Boston, Massachusetts, SevOne has expanded its presence with additional offices in Newark, Delaware, and London, United Kingdom. As of late 2019, SevOne operates as a subsidiary of Turbonomic, Inc.
At CampaignerCRM™, a j2® Global company, we're passionate about providing you with powerful CRM software that makes your sales process more efficient and gets you sales, revenue and customer results. We know that even the best sales people excel when they can focus on what they do best instead of being tied up generating forecasts, reports or entering data. That’s why we built CampaignerCRM. We put in all of the powerful features and functionality that make a sales team successful. Now your sales team can be free to focus on what it takes to make the sale. Your sales managers and executives automatically have accurate sales forecasting and the CRM reporting they need to stay up to speed on what’s going on in their sales pipeline. Most importantly, we made it all secure and easy-to-use with three solutions to help you manage your sales process.
Kolltan Pharmaceuticals, Inc. is a clinical-stage biotechnology company founded in 2007 and based in New Haven, Connecticut. The company focuses on the discovery and development of novel antibody-based drugs targeting receptor tyrosine kinases (RTKs) for the treatment of cancer and other diseases. Its lead product candidate, KTN3379, is an antibody targeting the ErbB3 RTK, currently undergoing Phase I clinical trials for advanced solid tumors. Additionally, Kolltan is developing KTN0158, a KIT RTK inhibitor aimed at treating neurofibromatosis type 1 and other inflammatory conditions, as well as an antibody-drug conjugate known as KIT-ADC for oncology applications. The company also engages in various research programs targeting RTKs, building on foundational discoveries made in collaboration with Dr. Joseph Schlessinger's laboratory at Yale University, which elucidate the molecular mechanisms linked to RTK activation and oncogenic mutations.
SevOne, Inc. specializes in infrastructure performance monitoring and analytics solutions for a global clientele, including communications service providers, government entities, financial institutions, and large enterprises. The company offers a comprehensive suite of products, including the SevOne Data Platform, which gathers multi-vendor network performance metrics and flow data, and the SevOne Data Insight, designed for customizable visualizations and workflows. Additionally, the SevOne Data Appliance analyzes network and infrastructure data, while the SevOne Data Bus streams real-time data. The SevOne Data Cloud provides both real-time and historical insights from network telemetry. The company also has solutions for monitoring software-defined networking (SDN) and SD-WAN for managed services providers. Founded in 2003 and headquartered in Boston, Massachusetts, SevOne has expanded its presence with additional offices in Newark, Delaware, and London, United Kingdom. As of late 2019, SevOne operates as a subsidiary of Turbonomic, Inc.
At CampaignerCRM™, a j2® Global company, we're passionate about providing you with powerful CRM software that makes your sales process more efficient and gets you sales, revenue and customer results. We know that even the best sales people excel when they can focus on what they do best instead of being tied up generating forecasts, reports or entering data. That’s why we built CampaignerCRM. We put in all of the powerful features and functionality that make a sales team successful. Now your sales team can be free to focus on what it takes to make the sale. Your sales managers and executives automatically have accurate sales forecasting and the CRM reporting they need to stay up to speed on what’s going on in their sales pipeline. Most importantly, we made it all secure and easy-to-use with three solutions to help you manage your sales process.